For complete information about the report, please visit our website
https://www.reportscorner.com/reports/23332/Innovative-Drug-Delivery-Systems:-Novel-Product-and-Formulation-Technology-Licensing-Opportunities-for-Generic-Pharmaceutical-Companies/
There are more than 1400 sustained or controlled release drugs have been approved all
over the world. Revenues within the global generics market reached an estimated value of
$265 b in 2012, showing a growth of 9.3% throughout the year. The contribution of
generics is approximately 20% of overall international pharmaceutical market. The
utilization of generic in terms of volume is higher in the US and lower in Japan, 89% and
24% respectively.
The oral drug delivery market remains the largest slice of the overall drug delivery
market, with more than 52% of the market share. It is presently valued at $49 billion and
is expected to reach over $90 billion by 2016, at a CAGR of 11%. The growth in the oral
drug delivery market shall be driven primarily by newer technologies enabling controlled
release formulations of oral drugs and oral formulations of injectable only drugs. Global
injectable drug delivery market is expected to be worth $29b by 2015.
Novel drug delivery systems (NDDS) offers many more advantages, which include
improved therapy by increasing the efficacy and duration of drug activity, increased
patient compliance through decreased dosing frequency and convenient routes of
administration and improved targeting for a specific site to reduce unwanted side effects.
The challenge for both drug and drug delivery companies is to deliver both existing and
emerging drug technologies in a manner that improves the benefits to the patients.
The generic market with reference to innovative molecule (NCE) has become very
competitive as several companies have already filed the ANDA for the potential generic
drugs in the near term. The study of novel drug delivery companies and their
formulation technologies will provide the potential value added opportunity in the
generic field in terms of patient’s compliance or bioavailability enhancement. It will also
provide enhanced life cycle for the drugs under patent coverage (life cycle extension).
This comprehensive report on novel drug delivery system focused mainly on oral and
injectable formulations for the pharma and specialty companies. This report enumerates
the various formulation technology involved in making value added formulations,
pharmaceutical applications and advantages of the specific technology. Wherever
available, the marketed drugs using the similar technology as the proof of validation and
the status of additional pipeline have also been discussed. The discussed proprietary
formulations technologies includes Colal, Glide SDI, Arestat, GeoClock, GeoMatrix,
FlashTab, Lock Tab, Medusa, Eligen, Oradur, EnteriCare and Saber.
This report will be helpful for the pharma companies exploring novel opportunities for
their growth by in-licensing the formulation technology or value added pipeline drugs
available/being studied in the market.
https://www.reportscorner.com/reports/23332/Innovative-Drug-Delivery-Systems:-Novel-Product-and-Formulation-Technology-Licensing-Opportunities-for-Generic-Pharmaceutical-Companies/
There are more than 1400 sustained or controlled release drugs have been approved all
over the world. Revenues within the global generics market reached an estimated value of
$265 b in 2012, showing a growth of 9.3% throughout the year. The contribution of
generics is approximately 20% of overall international pharmaceutical market. The
utilization of generic in terms of volume is higher in the US and lower in Japan, 89% and
24% respectively.
The oral drug delivery market remains the largest slice of the overall drug delivery
market, with more than 52% of the market share. It is presently valued at $49 billion and
is expected to reach over $90 billion by 2016, at a CAGR of 11%. The growth in the oral
drug delivery market shall be driven primarily by newer technologies enabling controlled
release formulations of oral drugs and oral formulations of injectable only drugs. Global
injectable drug delivery market is expected to be worth $29b by 2015.
Novel drug delivery systems (NDDS) offers many more advantages, which include
improved therapy by increasing the efficacy and duration of drug activity, increased
patient compliance through decreased dosing frequency and convenient routes of
administration and improved targeting for a specific site to reduce unwanted side effects.
The challenge for both drug and drug delivery companies is to deliver both existing and
emerging drug technologies in a manner that improves the benefits to the patients.
The generic market with reference to innovative molecule (NCE) has become very
competitive as several companies have already filed the ANDA for the potential generic
drugs in the near term. The study of novel drug delivery companies and their
formulation technologies will provide the potential value added opportunity in the
generic field in terms of patient’s compliance or bioavailability enhancement. It will also
provide enhanced life cycle for the drugs under patent coverage (life cycle extension).
This comprehensive report on novel drug delivery system focused mainly on oral and
injectable formulations for the pharma and specialty companies. This report enumerates
the various formulation technology involved in making value added formulations,
pharmaceutical applications and advantages of the specific technology. Wherever
available, the marketed drugs using the similar technology as the proof of validation and
the status of additional pipeline have also been discussed. The discussed proprietary
formulations technologies includes Colal, Glide SDI, Arestat, GeoClock, GeoMatrix,
FlashTab, Lock Tab, Medusa, Eligen, Oradur, EnteriCare and Saber.
This report will be helpful for the pharma companies exploring novel opportunities for
their growth by in-licensing the formulation technology or value added pipeline drugs
available/being studied in the market.
No comments:
Post a Comment